Jill Carroll

Jill Carroll is currently Director at ZappRx, Inc., Pandion Operations, Inc., Gotham Therapeutics Corp., HotSpot Therapeutics, Inc., TBio LLC, and Ancora Biotech LLC.
Ms. Carroll is Independent Director at Avalyn Pharma, Inc. since 2023.
Ms. Carroll is Partner at GSK Equity Investments Ltd. since 2011 and Operating Partner at SR One Capital Management LP since 2011.
Former roles include Senior Director-Corporate Development at Dynavax Technologies Corp.
from 2004 to 2010, Director at Neoantigenics, Inc., Director at Odyssey Therapeutics, Inc. from 2021 to 2026, Independent Director at Beacon Therapeutics (USA), Inc. in 2014, Independent Director at Arcellx, Inc. from 2017 to 2026, Director at Clearview Projects, Inc. from 2001 to 2004, Director at Second Genome, Inc., Director at Arch Oncology, Inc., Independent Director at Pandion Therapeutics, Inc. from 2019 to 2021, Director at Nkarta, Inc. from 2017 to 2020, Senior Associate at GSK Equity Investments Ltd., and Vice President-Corporate Development at Limerick BioPharma, Inc. in 2011.
Education includes graduate studies at The Johns Hopkins University and undergraduate degree from Duke University conferred in 1997.